Protalix BioTherapeutics (PLX) Reports Q4 Loss of $0.29/Share
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.17 +0.46%
Revenue Growth %: -49.8%
Financial Fact:
NET LOSS FOR THE PERIOD: -7.29M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: -49.8%
Financial Fact:
NET LOSS FOR THE PERIOD: -7.29M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q4 EPS of ($0.29), versus ($0.36) reported last year. Revenue for the quarter came in at $4.4 million, versus $3.5 million reported last year.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- CVG to join Russell 2000 and Russell 3000 indexes June 26
- Worthington Industries (WOR) Misses Q4 EPS by 9c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
